The Experts below are selected from a list of 98208 Experts worldwide ranked by ideXlab platform
Steven A Curley - One of the best experts on this subject based on the ideXlab platform.
-
neither neoAdjuvant nor Adjuvant Therapy increases survival after biliary tract cancer resection with wide negative margins
Journal of Gastrointestinal Surgery, 2012Co-Authors: Jean Nicolas Vauthey, Evan S Glazer, Eddie K Abdalla, Steven A CurleyAbstract:Background We investigated the role of neoAdjuvant/Adjuvant therapies on survival for resectable biliary tract cancer. We hypothesized that neoAdjuvant and Adjuvant Therapy should improve the survival probability in these patients.
Evan S Glazer - One of the best experts on this subject based on the ideXlab platform.
-
neither neoAdjuvant nor Adjuvant Therapy increases survival after biliary tract cancer resection with wide negative margins
Journal of Gastrointestinal Surgery, 2012Co-Authors: Jean Nicolas Vauthey, Evan S Glazer, Eddie K Abdalla, Steven A CurleyAbstract:Background We investigated the role of neoAdjuvant/Adjuvant therapies on survival for resectable biliary tract cancer. We hypothesized that neoAdjuvant and Adjuvant Therapy should improve the survival probability in these patients.
Peter M. Ravdin - One of the best experts on this subject based on the ideXlab platform.
-
Overview of Randomized Trials of Systemic Adjuvant Therapy
Cancer treatment and research, 2008Co-Authors: Peter M. RavdinAbstract:The most influential analyses of the effectiveness of systemic Adjuvant Therapy of breast cancer are the 3 overview meta-analyses performed at Oxford and published in 19881, 19922, and 19983. These meta-analyses are a collaborative effort dependent on pooling of data by trialists of nearly all the randomized clinical trials of systemic Adjuvant therapies. The major questions that were addressed by these Overview analyses were: 1) Is systemic Adjuvant Therapy of breast cancer effective? 2) Are there subsets of patients in whom given Adjuvant therapies are particularly effective? 3) How effective is the current Adjuvant Therapy?
-
computer program to assist in making decisions about Adjuvant Therapy for women with early breast cancer
Journal of Clinical Oncology, 2001Co-Authors: Peter M. Ravdin, Laura A Siminoff, Greg J Davis, Mary Beth Mercer, Joan Hewlett, Nancy Gerson, Helen L ParkerAbstract:PURPOSE: The goal of the computer program Adjuvant! is to allow health professionals and their patients with early breast cancer to make more informed decisions about Adjuvant Therapy. METHODS: Actuarial analysis was used to project outcomes of patients with and without Adjuvant Therapy based on estimates of prognosis largely derived from Surveillance, Epidemiology, and End-Results data and estimates of the efficacy of Adjuvant Therapy based on the 1998 overviews of randomized trials of Adjuvant Therapy. These estimates can be refined using the Prognostic Factor Impact Calculator, which uses a Bayesian method to make adjustments based on relative risks conferred and prevalence of positive test results. RESULTS: From the entries of patient information (age, menopausal status, comorbidity estimate) and tumor staging and characteristics (tumor size, number of positive axillary nodes, estrogen receptor status), baseline prognostic estimates are made. Estimates for the efficacy of endocrine Therapy (5 years of...
Ahmad A. Tarhini - One of the best experts on this subject based on the ideXlab platform.
-
Melanoma Adjuvant Therapy
Chinese clinical oncology, 2014Co-Authors: Prashanth M. Thalanayar, Sanjiv S. Agarwala, Ahmad A. TarhiniAbstract:The risk of recurrence and death after complete surgical resection of clinically detectable primary cutaneous melanoma ranges from low, intermediate to high risk depending on the stage of disease at diagnosis. This is defined by the depth, ulceration status and mitotic rate of the primary tumor, the presence of regional nodal disease or distant metastasis. For high-risk melanoma, Adjuvant Therapy aims at eradicating melanoma micrometastases in those patients that carry an unacceptable risk of mortality from melanoma recurrence. The ultimate goal of Adjuvant Therapy is to provide a potential cure before progression into advanced inoperable stages. After decades of randomized clinical trials, interferon-α alone has been shown to have a significant impact on relapse free survival and at high dosage on overall survival. These survival benefits were seen in comparison to observation (E1684 trial) and the ganglioside GMK vaccine (E1694 trial). Advances in our understanding of melanoma molecular biology and host immunology have given ways to novel targets and therapeutic agents that have demonstrated unprecedented results in the management of metastatic disease and currently are being tested in the Adjuvant stetting where recent data support a significant clinical impact of Adjuvant ipilimumab. Here, we review the standard of care melanoma Adjuvant Therapy along with the main completed, current and planned clinical trials.
-
Melanoma Adjuvant Therapy
Hematology-oncology Clinics of North America, 2014Co-Authors: Ahmad A. Tarhini, Prashanth M. ThalanayarAbstract:Adjuvant Therapy targets melanoma micrometastases in patients with surgically resected disease that carry a high risk of death from melanoma recurrence. In this setting, Adjuvant Therapy provides the greatest opportunity for cure before progression into advanced inoperable stages. In randomized clinical trials, interferon-alfa has been shown to have a significant impact on relapse-free survival and, at high dosage, on overall survival compared with observation (E1684) and the GMK vaccine (E1694). This article reviews melanoma Adjuvant Therapy along with the ongoing and planned clinical trials.
-
Comparative clinical benefits of systemic Adjuvant Therapy for paradigm solid tumors
Cancer Treatment Reviews, 2012Co-Authors: John M. Kirkwood, Ahmad A. Tarhini, Joseph A. Sparano, Prapti A. Patel, Joan H. Schiller, Maxwell T. Vergo, Al B. Benson, Hussein TawbiAbstract:Abstract Adjuvant Therapy employing cytotoxic chemoTherapy, molecularly targeted agents, immunologic, and hormonal agents has shown a significant impact upon a variety of solid tumors. The principles that guide Adjuvant Therapy differ among various tumor types and specific modalities, but generally indicate a greater impact of Therapy in the postsurgical setting of micrometastatic disease, for which Adjuvant Therapy is commonly pursued, vs. the setting of gross unresectable disease. This review of Adjuvant therapies in current use for five major solid tumors highlights the rationale for current effective Adjuvant Therapy, and draws comparisons between the Adjuvant regimens that have found application in solid tumors.
-
Adjuvant Therapy for melanoma.
Cancer Journal, 2012Co-Authors: Diwakar Davar, Ahmad A. Tarhini, John M. KirkwoodAbstract:Estimates from the U.S. Surveillance, Epidemiology, and End Results registry suggest that melanoma incidence will reach 70,230 cases in 2011, of whom 8790 will die. The rising incidence and predilection for young individuals makes this tumor a leading source of lost productive years in the society.High-dose interferon-α-2b is the only agent approved for Adjuvant Therapy for melanoma; the improvement in relapse-free survival has been observed across nearly all published studies and meta-analyses. However, toxicity affects compliance, and current research is focusing on biomarkers that may allow selection of patients with greater likelihood of response and exploring new agents either singly or in combination that may improve on the benefit of interferon.In this article, we review the data for the Adjuvant Therapy for malignant melanoma--focusing on the results obtained with various regimens testing the several formulations of interferon-α2 and the Adjuvant studies of vaccines and radioTherapy. Recent advances in the treatment of metastatic disease have established a role for CTLA-4 blockade and BRAF-inhibition, raising hopes that these agents may have a role in the Adjuvant setting. At present, several trials investigating combinations of novel agents with existing immunomodulators are underway.
Tom Brody - One of the best experts on this subject based on the ideXlab platform.
-
Chapter 17 – NeoAdjuvant Therapy Versus Adjuvant Therapy
Clinical Trials, 2016Co-Authors: Tom BrodyAbstract:This chapter describes an aspect of study design for oncology clinical trials (and in daily oncology clinical practice), namely, the choice of neoAdjuvant Therapy, which occurs before surgery, and Adjuvant Therapy, which occurs after Therapy. NeoAdjuvant Therapy and Adjuvant Therapy each have specific advantages. Often, clinical trials in oncology include study arms that test both of these approaches to study design.
-
NeoAdjuvant Therapy versus Adjuvant Therapy
Clinical Trials, 2012Co-Authors: Tom BrodyAbstract:This chapter describes an aspect of study design for oncology clinical trials (and in daily oncology clinical practice), namely, the choice of neoAdjuvant Therapy, which occurs before surgery, and Adjuvant Therapy, which occurs after Therapy. NeoAdjuvant Therapy and Adjuvant Therapy each have specific advantages. Often, clinical trials in oncology include study arms that test both of these approaches to study design.
